Detalles de la búsqueda
1.
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
J Oncol Pharm Pract
; 29(2): 457-464, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36344039
2.
Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.
J Oncol Pharm Pract
; 29(4): 958-961, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36823960
3.
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.
J Oncol Pharm Pract
; 28(3): 691-694, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34994227
4.
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma.
J Oncol Pharm Pract
; 28(2): 434-437, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581219
5.
Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
J Oncol Pharm Pract
; 28(1): 199-202, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581610
6.
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
J Oncol Pharm Pract
; 27(5): 1245-1247, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34018861
7.
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
J Oncol Pharm Pract
; 27(2): 445-447, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356990
8.
Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
J Oncol Pharm Pract
; 27(4): 974-977, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33541208
9.
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
Curr Opin Oncol
; 32(4): 269-273, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32541312
10.
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
J Oncol Pharm Pract
; 26(6): 1486-1491, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576084
11.
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Pancreatology
; 19(2): 325-330, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30704852
12.
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.
Int J Colorectal Dis
; 33(11): 1505-1516, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30196427
13.
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs.
Int J Colorectal Dis
; 33(10): 1487-1491, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29804191
14.
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Int J Gynecol Cancer
; 27(9): 1872-1876, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28976446
15.
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
J Oncol Pharm Pract
; 28(7): 1674-1676, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35833215
16.
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.
J Oncol Pharm Pract
; 28(1): 194-198, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34558365
17.
Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change.
J Oncol Pharm Pract
; 28(2): 438-441, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34609930
18.
Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic.
J Med Virol
; 93(1): 118-119, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32779798
19.
COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research management.
J Med Virol
; 93(5): 2564-2565, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33215735
20.
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Int J Colorectal Dis
; 36(1): 197-198, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32929530